Characterization of T‐DM1‐resistant breast cancer cells

Acquired Resistance to Antibody-Drug Conjugates

(2019) Denis Collins et al.   Cancers

Unraveling ‘The Cancer Genome Atlas’ information on the role of SLC transporters in anticancer drug uptake

(2019) Ruba Al-Abdulla et al.   Expert Review of Clinical Pharmacology

Lysosomal dysfunction in proteinopathic neurodegenerative disorders: possible therapeutic roles of cAMP and zinc

(2019) Jae-Young Koh et al.   Molecular Brain

Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

(2019) Rasha M. Sareyeldin et al.   Cancers

Determinants and clinical implications of chromosomal instability in cancer

(2018) Laurent Sansregret et al.   Nature Reviews Clinical Oncology

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

(2018) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle

(2017) Lorenzo Gerratana et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

HER2-positive breast cancer

(2017) Sibylle Loibl et al.   LANCET

Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy

(2017) Teresa Davoli et al.   SCIENCE

Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade

(2016) Zhaolin Chen et al.   CANCER LETTERS

Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature

(2016) María Teresa Martínez et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy

(2016) Angelika Dlugosz et al.   CURRENT PHARMACEUTICAL DESIGN

Mechanisms of Resistance to Antibody–Drug Conjugates

(2016) Frank Loganzo et al.   MOLECULAR CANCER THERAPEUTICS

Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib

(2015) J. C. Byrd et al.   BLOOD

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort

(2015) Anne-Sophie Hamy-Petit et al.   BRITISH JOURNAL OF CANCER

SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm

(2015) K. J. Hamblett et al.   CANCER RESEARCH

MRP1 and its role in anticancer drug resistance

(2015) Jamie F. Lu et al.   DRUG METABOLISM REVIEWS

Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments

(2015) F. Loganzo et al.   MOLECULAR CANCER THERAPEUTICS

CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin

(2015) R. Chen et al.   MOLECULAR CANCER THERAPEUTICS

SLC transporters as therapeutic targets: emerging opportunities

(2015) Lawrence Lin et al.   NATURE REVIEWS DRUG DISCOVERY

Trastuzumab emtansine: mechanisms of action and drug resistance

(2014) Mark Barok et al.   BREAST CANCER RESEARCH

Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches

(2014) Qiong Wu et al.   CANCER LETTERS

Zn2+ efflux through lysosomal exocytosis prevents Zn2+-induced toxicity

(2014) I. Kukic et al.   JOURNAL OF CELL SCIENCE

Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer

(2014) John M. Lambert et al.   JOURNAL OF MEDICINAL CHEMISTRY

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

(2013) Sara A. Hurvitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sodium/hydrogen exchanger NHA2 is critical for insulin secretion in  -cells

(2013) C. Deisl et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Drug-conjugated antibodies for the treatment of cancer

(2012) John M. Lambert   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Causes and consequences of aneuploidy in cancer

(2012) David J. Gordon et al.   NATURE REVIEWS GENETICS

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

p95HER2 and Breast Cancer

(2011) J. Arribas et al.   CANCER RESEARCH

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

(2010) Teemu T. Junttila et al.   BREAST CANCER RESEARCH AND TREATMENT

Microtubule-binding agents: a dynamic field of cancer therapeutics

(2010) Charles Dumontet et al.   NATURE REVIEWS DRUG DISCOVERY